Lantern Pharma Inc. (NASDAQ: LTRN) reported its financial results for the third quarter ended September 30, 2026, and announced several operational updates. The company closed a registered direct offering and concurrent private placement on September 30, 2026, raising gross proceeds of approximately $4.0 million. As of September 30, 2026, the company held cash, cash equivalents, and marketable securities totaling approximately $7.6 million.

Regarding operating results, Research and Development (R&D) expenses decreased approximately 36% year over year to approximately $1.6 million for the third quarter of 2026. The loss from operations for the quarter was approximately $5.4 million, which included a $2.0 million accrual related to a proposed settlement with a former part-time consultant. Excluding this accrual, the loss from operations was approximately $3.4 million.

In leadership news, Panna Sharma resigned as President and Chief Executive Officer and as a member of the Board of Directors on November 15, 2026. Effective November 16, 2026, the Board appointed David Margrave, the company’s Chief Financial Officer, as Interim Chief Executive Officer until a permanent successor is appointed.

Operational highlights for the quarter included the engagement of the first clinical site for a Phase 1b/2 trial of LP-184 in triple-negative breast cancer, which received Fast Track designation from the FDA. Lantern also reported that the Taiwan Food and Drug Administration approved the amended protocol for Part 2 of the Phase 2 HARMONIC trial of LP-300 in L858R never-smoker non-small cell lung cancer, with the lead site open for patient accrual. Additionally, a peer-reviewed publication of Phase 1a data for LP-184 in recurrent glioblastoma was released in October 2026, supporting a planned Phase 1b/2a combination trial with spironolactone.